MC2 Plots Course For Topical Psoriasis Drug Launch After Positive Phase III Data
Executive Summary
The Danish company is planning to file an NDA with the US FDA in 2019 after reporting positive Phase III data showing the topical cream MC2-01 was superior to Leo Pharma's Taclonex.